Compass Pathways to announce first quarter 2026 financial results on May 13, 2026, with a corporate update and webcast for investors and stakeholders

Compass Pathways plans to report its first quarter 2026 financial results on May 13, 2026 and pair the release with a corporate update and webcast for investors. The company is a public biotech focused on developing psilocybin-based mental health treatments, so the announcement sits within broader investor tracking of its clinical and commercial progress. The event centers on financial performance, management commentary, and access details for shareholders and market observers. For psychedelic medicine, Compass remains a prominent industry actor because its business milestones, trial progress, and capital position influence expectations around the regulated development of psilocybin therapies.